tbuckley/cabot-search huggingface dataset:
Abstract 1504: Dual effect of MMP-9 and its fibronectin-like domain in tumor growth and invasion
Authors: Cynthia Dayer, Carlo Fusco, Marie-Aude Le-Bitoux, Ivan Stamenkovic
Journal: Cancer Research (2012)

Abstract Tumors are often compared to wounds that do not heal, where the crosstalk between tumor cells and their surrounding stroma is crucial at all stages of development from the initial primary growth to metastasis. Similar to wound healing, fibroblasts in the tumor stroma differentiate into myofibroblasts, also referred to as “cancer-associated fibroblasts” (CAFs), primarily, but not exclusively, in response to transforming growth factor-β (TGF-β). Myofibroblasts in turn enhance tumor progression by remodeling the stroma. Among molecules implicated in stromal remodeling, matrix metalloproteinases (MMPs), and MMP-9 in particular, play a prominent role. However, the mechanisms that regulate MMP-9 activation and function remain poorly understood. Recent evidence indicates that tumor cell surface association of MMP-9 is an important event in its activation, and more generally in tumor growth and invasion. Based on these observations, we addressed the potential association of MMP-9 activity with cell-surface recruitment on human fibroblasts. We show for the first time that recruitment of MMP-9 to the MRC5 fibroblast cell surface occurs through the fibronectin-like (FN) domain, found only in MMP-9 and MMP-2. Functional assays suggest that the active form of MMP-9 triggers α-smooth muscle actin (αSMA) expression in resting fibroblasts that reflects myofibroblast differentiation, possibly through TGF-β activation. Preliminary xenograft experiments using HT1080 fibrosarcoma or MDA-MD231 breast adenocarcinoma cells stably expressing the FN domain of MMP-9 in NOD/SCID mice revealed decreased primary tumor growth suggesting that the FN domain alone can displace MMP-9 proteolytic activity from the cell surface. However, in the context of metastasis, expression of the FN domain by these same tumor cells dramatically increases their metastatic proclivity whereas expression of wt MMP-9 either promotes no change or actually reduces the number of metastases. These observations suggest a dual role of MMP-9 and its FN domain in primary tumor growth and metastasis, illustrating protective effects of MMPs in tumor progression and invasion. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1504. doi:1538-7445.AM2012-1504
Obstructive Ileal Ascariasis
Authors: Aruyaru Stanley Mwenda, John Hamad Ilkul
Journal: New England Journal of Medicine (2013)

A 10-year-old Kenyan girl presented with abdominal pain that had worsened over a period of 3 days. Vomiting and abdominal distention had also developed. On examination, she was cachectic, with a distended abdomen and a soft, tender mass at the right iliac fossa.
An unusual cause of hemosuccus pancreaticus diagnosed by endoscopic ultrasonography: splenic arterial fistula due to a pancreatic stent (with video)
Authors: A. Seicean, R. Stan-Iuga, D. Munteanu
Journal: Endoscopy (2010)

We report the case of a 54-year-old woman recently diagnosed with severe acute biliary pancreatitis requiring surgical necrosectomy and caudal pancreatectomy 1 month later. After surgery the patient developed an internal pancreatic fistula which was treated with octreotide (Sandostatin) and percutaneous drainage. Two months later she was diagnosed with a large pancreatic pseudocyst communicating with the pancreatic duct. A transpapillary plastic stent was placed with favorable outcome. After 2 months intermittent rectal bleeding occurred.
AB0883 Evaluating patient-reported outcomes in patients with early spondyloarthritis in the desir cohort:
Authors: G.H. Louie, D. van der Heijde, M. Dougados, C.O. Bingham
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Most patient-reported outcomes (PROs) for spondyloarthritis (SpA) were developed in ankylosing spondylitis (AS) and concentrate on pain and function. Disease-specific PROs are not well-studied in patients (pts) with early inflammatory back pain (IBP). DESIR (DEvenir Spondyloarthropathies Indifferenciées Récentes) is a French multicenter, prospective longitudinal cohort study of pts (n=708) with early IBP (Cailin or Berlin criteria) and 3-35 mos of SpA symptoms by investigator assessment (≥5 on 0-10 scale; 0=no suggestion, 10=high suggestion). <h3>Objectives</h3> To examine existing SpA PROs in pts with early IBP. <h3>Methods</h3> Using DESIR, we tested correlations of baseline (BL) scores on disease-specific PROs in early SpA [Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), and Bath Ankylosing Spondylitis Functional Index (BASFI)] using Pearson's correlation coefficients. We then analyzed BL scores by pt subgroups (e.g. peripheral arthritis, enthesitis, uveitis, psoriasis (PsO), anterior chest wall pain, and inflammatory bowel disease (IBD)). <h3>Results</h3> Among 708 early SpA pts (mean age 33.8±8.6 yrs, 46.2% men, 57.9% HLA-B27 positive, mean symptoms 18.4±11.2 mos) mean BL ASQoL, BASDAI, and BASFI were 9.3±5.0, 4.5±2.0, and 3.0±2.4, respectively. Correlations between BL ASQoL, BASDAI, and BASFI ranged from r=0.68-0.70. Higher scores on the 3 instruments were observed in pts with peripheral arthritis, enthesitis, PsO, anterior chest wall pain, and IBD than in patients without these SpA clinical features (Table). Lower scores on the PROs were observed in pts with uveitis than in those without. <h3>Conclusions</h3> The modest correlations between the different PROs (e.g. ASQoL, BASDAI, BASFI) suggest that these PROs are evaluating different facets or aspects of the patients' condition. Moreover, this study suggests also that the impact of the disease on the patients' condition is similar across the different clinical sub-groups of the SpA disease. <h3>Disclosure of Interest</h3> None Declared
Abstract 5077: Anti-angiogenesis and anti-cancer activities of ZK002, a C-type lectin-like protein isolated from snake venom.
Authors: Shan Yu, Xiangrong Dai, William C.S. Tai, Roy C.Y. Choi, Chaofan Liang, Benjamin X.y. Li, Karl W.K. Tsim, Wendy W.L. Hsiao
Journal: Cancer Research (2013)

Abstract Snake venoms contain various biologically active proteins including C-type lectins and -like proteins (CTLs), phospholipases, proteinases and metalloproteinases, that could target diverse cellular processes. Among these active components, CTLs have demonstrated antithrombotic effects through their platelet agglutination and coagulation activities. In our study, we have detected anti-angiogenesis activity from the venom of Deinagkistrodon acutus snake. The partial purified fraction of snake venom with anti-angiogenesis activity was isolated through a stepwise separation in anion-exchange and cation-exchange chromatography. At the same time, the monoclonal antibody was generated and used for further protein purification by affinity chromatography. This highly purified protein was named as ZK002. By MALDI-TOF mass spectrometry determination, the mass of ZK002 is about 30KD. By LC-MS/MS analysis, protein sequence of highly purified ZK002 was determined and compared with the Deinagkistrodon acutus snake protein database. ZK002 is a heterodimer of CTLs consisting of alpha and beta peptide chains. Using In vitro chicken embryo chorioallantoic membrane assay and human umbilical vein endothelial cell (HUVEC) tube formation assay, it showed that ZK002 exhibited an anti-angiogenesis effect. Moreover, ZK002 also demonstrated an anti-cancer effect as shown in the ApcMin/+ mouse model for colorectal cancer. Administration of ZK002 significantly suppressed the total number and the size of tumors and showed no observable adverse effect. To further elucidate the anti-angiogenesis functions of ZK002, we deduced the coding DNA sequences from the peptide sequences of the alpha- and beta-chains, then subcloned individual gene sequence into yeast and mammalian expression vectors. Results showed that the recombinant vectors express secreted peptides with the expected molecular weight. Transient transfection of the alpha- and beta-recombinant vectors individually or in combination inhibit tube formation in HUVEC cells, suggesting that both alpha- and beta-chains possess anti-angiogenesis activity. The success of cloning and expression of recombinant ZK002 would greatly facilitate the future development of ZK002 as anti-angiogenesis and anti-cancer drugs. (This work is supported by the Innovation and Technology Fund (UIM208) of Hong Kong Government) Citation Format: Shan Yu, Xiangrong Dai, William C.S. Tai, Roy C.Y. Choi, Chaofan Liang, Benjamin X.y. Li, Karl W.K. Tsim, Wendy W.L. Hsiao. Anti-angiogenesis and anti-cancer activities of ZK002, a C-type lectin-like protein isolated from snake venom. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 5077. doi:10.1158/1538-7445.AM2013-5077
Abstract 1119: Interplay between EGFRvIII and c-Met in glioblastoma multiforme
Authors: Vanessa Saunders, Yuan Yuan Ling, Jessica Anderson, Derek Duckett
Journal: Cancer Research (2011)

Abstract Glioblastoma multiforme (GBM) is a highly invasive and lethal brain tumor which is associated with a high recurrence rate after surgery and an increased resistance to irradiation and chemotherapies. Consequently, patients suffering from GBM have a poor prognosis and a high mortality rate with an average life expectancy of less than 15 months. Key signaling components, especially receptor tyrosine kinases (RTKs), are aberrantly activated in GBM. The most frequent is the epidermal growth factor receptor (EGFR) and here the most commonly activated form, EGFRvIII, augments GBM invasiveness, promotes therapy resistance and connotes poor prognosis. There are five EGFR approved inhibitors and interestingly clinical studies have indicated that targeting the activity of the EGFR in association with conventional GBM therapies does little to inhibit tumor growth. The underlying mechanistic reasoning for this poor response are not understood and may reflect EGFR-induced trans-activation of other RTKs such as the hepatocyte growth factor receptor (c-Met), or uncoupling of EGFR signaling from its downstream mediators. Several studies have indicated that EGFR can trans-activate c-Met and consequently the dual targeting of both EGFR and c-Met significantly decreases the growth of EGFRvIII expressing tumor xenografts, indicating that inhibiting both EGFR and c-Met activity may prove beneficial in GBM therapy. Currently, the only known ligand for c-Met is the hepatocyte growth factor (HGF). Thus we hypothesize that EGFR induced HGF production is critical for the increased tumorgenicity observed in EGFRvIII expressing GBM cells. Using GBM cell lines we show that c-Met activation is increased in GBM cells that both stably and transiently express EGFRvIII. Furthermore, conditioned media taken from GBM cells expressing EGFRvIII can activate c-Met signaling in GBM cells that lack EGFRvIII. In both instances we see that the kinase activity of the EGFRvIII partially contributes to the production of HGF and the activation of c-Met in GBM cells. Aberrant c-Jun terminal kinase signaling (JNK) can be detected in the majority of patient GBMs. Using GBM cells stably lacking JNK2α2 we identify JNK2α2 signaling as a potential mechanism behind EGFRvIII activation of c-Met via the production of HGF in EGFRvIII GBM expressing cells. Taken together our data describes a novel role for JNK2α2 in mediating GBM tumorgenicity through the regulation of HGF production and the subsequent activation of c-Met signaling in GBM. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1119. doi:10.1158/1538-7445.AM2011-1119
Planning and Conducting Meetings Effectively, Part III
Authors: Jay A. Harolds
Journal: Clinical Nuclear Medicine (2012)

The attendees at a meeting have different ways in which they get information and make decisions, different personal needs, and different ways in which they participate in groups. Some have counterproductive behaviors in committee meetings, such as attacking others, talking too long but not saying much, talking too little, deliberately trying to undermine the process, bringing up unrelated issues, engaging in private conversations with others, or silencing others. The chairperson must meet all of these challenges to have a productive meeting. This article gives some tips on how to run meetings well.
Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission
Authors: DS Snyder, AP Nademanee, MR O’Donnell, PM Parker, AS Stein, K Margolin, G Somlo, A Molina, R Spielberger, A Kashyap, H Fung, ML Slovak, A Dagis, RS Negrin, MD Amylon, KG Blume, SJ Forman
Journal: Leukemia (1999)
CC10 A38G Polymorphism (rs3741240) Is Associated with Asthma Susceptibility and Bronchial Hyperresponsiveness Mediated by the Eosinophilic Inflammation in Korean Children
Authors: Kyungmo Hong, Hyun-Kyung Kim, Mi-Jin Kang, Ho-Sung Yu, Byoung-Ju Kim, Young Ho Jung, Jinho Yu, Soo-Jong Hong
Journal: Journal of Allergy and Clinical Immunology (2013)
Transmural Ventricular Pressures in Experimental Cardiac Tamponade
Authors: NOBLE O. FOWLER, RALPH SHABETAI, JOHN R. BRAUNSTEIN
Journal: Circulation Research (1959)

Experimental cardiac tamponade was produced in open-chest dogs. Left and right ventricular systolic pressures fell when intrapericardial pressure was increased only a few millimeters of mercury. Negative diastolic transmural pressures of 1 to 6 mm. Hg developed in the left ventricle and negative diastolic transmural pressures of 2 to 8.5 mm. Hg developed in the right ventricle. In some instances the period of right ventricular systolic ejection was greatly abbreviated at higher levels of intrapericardial pressure.
Core biopsy needle versus standard aspiration needle for endoscopic ultrasound-guided sampling of solid pancreatic masses: a randomized parallel-group study
Authors: Yun Lee, Jong Moon, Hee Kim, Hyun Choi, Moon Choi, Dong Kim, Tae Lee, Sang-Woo Cha, Young Cho, Sang-Heum Park
Journal: Endoscopy (2014)

<b>Background and study aims:</b> An endoscopic ultrasound (EUS)-guided fine needle biopsy (EUS-FNB) device using a core biopsy needle was developed to improve diagnostic accuracy by simultaneously obtaining cytological aspirates and histological core samples. We prospectively compared the diagnostic accuracy of EUS-FNB with standard EUS-guided fine needle aspiration (EUS-FNA) in patients with solid pancreatic masses. <b>Patients and methods:</b> Between January 2012 and May 2013, consecutive patients with solid pancreatic masses were prospectively enrolled and randomized to undergo EUS-FNB using a core biopsy needle or EUS-FNA using a standard aspiration needle at a single tertiary center. The specimen was analyzed by onsite cytology, Papanicolaou-stain cytology, and histology. The main outcome measure was diagnostic accuracy for malignancy. The secondary outcome measures were: the median number of passes required to establish a diagnosis, the proportion of patients in whom the diagnosis was established with each pass, and complication rates. <b>Results:</b> The overall accuracy of combining onsite cytology with Papanicolaou-stain cytology and histology was not significantly different for the FNB (n = 58) and FNA (n = 58) groups (98.3 % [95 %CI 94.9 % – 100 %] vs<i>.</i> 94.8 % [95 %CI 91.9 % – 100 %]; <i>P</i> = 0.671). Compared with FNA, FNB required a significantly lower median number of needle passes to establish a diagnosis (1.0 vs<i>.</i> 2.0; <i>P</i> < 0.001). On subgroup analysis of 111 patients with malignant lesions, the proportion of patients in whom malignancy was diagnosed on the first pass was significantly greater in the FNB group (72.7 % vs<i>.</i> 37.5 %; <i>P</i> < 0.001). <b>Conclusions:</b> The overall accuracy of FNB and FNA in patients with solid pancreatic masses was comparable; however, fewer passes were required to establish the diagnosis of malignancy using FNB. This study was registered on the UMIN Clinical Trial Registry (UMIN000014057).
Unconventional Methods Under Review by NIH
Authors: F. X. Mahaney
Journal: JNCI Journal of the National Cancer Institute (1992)

Journal Article Unconventional Methods Under Review by NIH Get access Francis X. Mahaney, Jr. Francis X. Mahaney, Jr. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 84, Issue 14, 15 July 1992, Page 1067, https://doi.org/10.1093/jnci/84.14.1067 Published: 15 July 1992
IMPACT OF RENAL DYSFUNCTION ON TRANSCATHETER AORTIC VALVE REPLACEMENT OUTCOME IN A LARGE MULTICENTER COHORT
Authors: Pablo Codner, Amos Levi, Giussepe Gargiulo, Fabien Praz, Kentaro Hayashida, Amer Masalha, Yusuke Watanabe, Darren Myllotte, Nicolas Debry, Marco Barbanti, Thierry Lefevre, Thomas Modine, Bosmans Johan, Stephan Windecker, Georg Nickenig, Israel Barbash, Jan-Malte Sinning, Alon Barsheshet, Ran Kornowski
Journal: Journal of the American College of Cardiology (2016)
ECHOCARDIOGRAPHIC PULMONARY/LEFT ATRIAL RATIO: A NOVEL AND ROBUST NON-INVASIVE DISCRIMINATOR OF PRE-CAPILLARY VERSUS POST-CAPILLARY PULMONARY HYPERTENSION
Authors: Gregory M. Scalia, Rebecca Kierle, Rebekka Beaumont, John Feenstra, David Cross
Journal: Journal of the American College of Cardiology (2015)
Radiation-Induced Chest-Wall Chondrosarcoma Following Surgical Resection and Radiotherapy for Non-Small-Cell Lung Cancer
Authors: EDWARD R. SAUTER, STEVEN M. KELLER, WALTER J. CURRAN, JOSE RUSSO, COREY J. LANGER
Journal: JNCI Journal of the National Cancer Institute (1993)

Journal Article Radiation-Induced Chest-Wall Chondrosarcoma Following Surgical Resection and Radiotherapy for Non-Small-Cell Lung Cancer Get access EDWARD R. SAUTER, EDWARD R. SAUTER Search for other works by this author on: Oxford Academic PubMed Google Scholar STEVEN M. KELLER, STEVEN M. KELLER Search for other works by this author on: Oxford Academic PubMed Google Scholar WALTER J. CURRAN, WALTER J. CURRAN Search for other works by this author on: Oxford Academic PubMed Google Scholar JOSE RUSSO, JOSE RUSSO Search for other works by this author on: Oxford Academic PubMed Google Scholar COREY J. LANGER COREY J. LANGER Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 85, Issue 2, 20 January 1993, Pages 162–163, https://doi.org/10.1093/jnci/85.2.162 Published: 20 January 1993
Effect of Diphenylhydantoin on Insulin Secretion in Man
Authors: Christian Malherbe, Karen C. Burrill, Seymour R. Levin, John H. Karam, Peter H. Forsham
Journal: New England Journal of Medicine (1972)

Blood glucose and serum insulin levels were measured in six normal subjects receiving an intravenous glucose priming load followed by a 2 1/2-hour constant glucose infusion. The test procedure was repeated in these subjects after three days of oral diphenylhydantoin (DPH) therapy (200 mg, three times daily). During both series of tests, high blood glucose levels were achieved throughout the infusion, and diphasic insulin responses were observed, characterized by an early peak and a late rise. DPH administration resulted in a significantly higher mean blood glucose response (+ 19 per cent, p less than 0.01) and significant diminution of early and late insulin responses (respectively, -60 per cent, p less than 0.01, and -39 per cent, p less than 0.05). These results demonstrated that DPH, known to inhibit insulin release in vitro, also diminished insulin response to an intensive and sustained glucose stimulation in man. Therefore, DPH should be used with special caution in patients who have a risk factor for diabetes or who are receiving other diabetogenic agents.
PTH-004 Subjective Description Of Pain Does Not Predict Biliary Manometry Or Response To Endotherapy In Sphincter Of Oddi Dysfunction: Are The Rome Criteria Fit For Purpose?
Authors: B Paranandi, VTF Cheung, D Joshi, GH El-Sayed, GJ Johnson, SP Pereira, GJ Webster, MH Chapman
Journal: Gut (2014)

<h3>Introduction</h3> In the absence of biochemical or radiological evidence of biliary obstruction, Sphincter of Oddi dysfunction (SOD) is a difficult condition to diagnose and to treat. The Rome III diagnostic criteria clearly state that, to meet a diagnosis of SOD, a patient should have “episodic pain at different time intervals (not daily)”. We observe heterogeneity in symptoms amongst patients referred with suspected SOD with many patients reporting constant daily pain requiring potent analgesia. We aim to determine whether subjective reporting of pain (according to the Rome criteria) correlates with Sphincter of Oddi Manometry (SOM: the gold standard for diagnosis of SOD) and/or response to endoscopic sphincterotomy/plasty (ES). <h3>Methods</h3> An ERCP database and electronic clinic lists (from September 2011 to 2013) were analysed to identify all cases of suspected SOD. Patients underwent a telephone questionnaire based on subjective recall of pre-ERCP pain according to the Rome criteria and post-ERCP response. Patients were asked to categorise pain as either intermittent with no pattern/not daily (Rome +ve) or daily/constant pain (Rome –ve). <h3>Results</h3> 163 new patients with suspected biliary SOD were identified of whom 89 underwent ERCP. They were mostly Female (87%), White British (86%) with median age 37 years (range 18–69). 48 patients with SOD2/3, who underwent SOM, agreed to answer the questionnaire. Patients with SOD1 do not routinely undergo SOM. Biliary and/or pancreatic basal pressures were abnormally elevated (&gt;40 mmHg) in 33/37 (89%) SOD2 and 8/10 (80%) SOD3, all of whom underwent ES. There were no significant correlations between Rome +ve pain and either biliary manometry (p = 0.3) <i>or</i> improvement in pain following ES (p = 0.2) in patients with either SOD 2 or 3 (see tables). However, there was a high relapse rate after initial improvement across both groups (SOD2 17/26=65%, SOD3 2/7=29%) irrespective of whether patients had Rome +ve or –ve pain initially. <h3>Conclusion</h3> Despite the clear recommendations of the Rome criteria requiring intermittent/episodic pain for a diagnosis of SOD, our data suggest that correlation between description of pain and biliary manometry is poor. 30–35% of patients who meet the current gold standards for diagnosis of SOD have constant or daily (Rome –ve) pain. Additionally, description of pain does not predict response to endotherapy suggesting that the Rome criteria and/or SOM for suspected SOD are not clinically useful and may need to be redefined. We note that high rates of positive SOM and recurrence of pain post-ES was seen in our cohort. <h3>Disclosure of Interest</h3> None Declared.